composition-dependent in vivo antitumor activity of adriamycin-conjugated polymeric micelle against murine colon adenocarcinoma 26

AbstractMicelle-forming block copolymer–drug conjugates, Adriamycin-conjugated polyethylene glycol–poly(aspartic acid) block copolymers (PEG-P[Asp(ADR)]), were synthesized in eight compositions with varying chain lengths of the segments constituting the block co-polymer. The antitumor activity of this micelle-forming polymeric anticancer drug against murine colon adenocarcinoma 26 (C 26) was evaluated by injection into the tail vein. The in vivo activity of the micelle-forming polymeric anticancer drug was revealed to be strongly dependent on the composition, while the in vitro cytotoxic activity was found to be in the same range regard-less of the composition. One composition of PEG–P[Asp(ADR)] was observed to significantly suppress tumor growth and to prolong survival of the treated mice in a wide dose range. These results indicated that selective delivery of the micelle-forming polymeric anti-cancer drug to the tumor was achieved by the appropriate composition of the block copolymer–drug conjugates.

[1]  K. Kataoka,et al.  Preparation of adriamycin-conjugated poly(ethylene glycol)-poly(aspartic acid) block copolymer. A new type of polymeric anticancer agent , 1987 .

[2]  J. Kopecek,et al.  Anticancer agents coupled to N-(2-hydroxypropyl)methacrylamide copolymers. I. Evaluation of daunomycin and puromycin conjugates in vitro. , 1987, British Journal of Cancer.

[3]  T. Okano,et al.  Characterization and anticancer activity of the micelle-forming polymeric anticancer drug adriamycin-conjugated poly(ethylene glycol)-poly(aspartic acid) block copolymer. , 1990, Cancer research.

[4]  M. Hashida,et al.  Disposition characteristics of mitomycin C-dextran conjugate in normal and tumor-bearing muscles of rabbits. , 1987, Cancer research.

[5]  A. Gabizon,et al.  Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[6]  J. Koziol,et al.  Preclinical trials with combinations and conjugates of T101 monoclonal antibody and doxorubicin. , 1986, Cancer research.

[7]  F. Zunino,et al.  Poly(carboxylic acid) polymers as carriers for anthracyclines , 1989 .

[8]  J. Feijen,et al.  OPTIMIZATION OF MACROMOLECULAR PRODRUGS OF THE ANTITUMOR ANTIBIOTIC ADRIAMYCIN , 1985 .

[9]  M. Bally,et al.  Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice. , 1989, Cancer research.

[10]  K. Fujimori,et al.  Modeling analysis of the global and microscopic distribution of immunoglobulin G, F(ab')2, and Fab in tumors. , 1989, Cancer research.

[11]  T. Okano,et al.  Molecular design for missile drug: Synthesis of adriamycin conjugated with immunoglobulin G using poly(ethylene glycol)-block-poly(aspartic acid) as intermediate carrier , 1989 .

[12]  R. Paxton,et al.  Mechanism of decreasing liver uptake of 111In-labeled anti-carcinoembryonic antigen monoclonal antibody by specific antibody pretreatment in tumor bearing mice. , 1990, Cancer research.

[13]  B. Wolff,et al.  Fate of Liposomes In Vivo: Control Leading to Targeting , 1984 .

[14]  Yokoyama Masayuki,et al.  Polymer micelles as novel drug carrier: Adriamycin-conjugated poly(ethylene glycol)-poly(aspartic acid) block copolymer , 1990 .

[15]  Y. Takeda,et al.  A novel covalent modification of antibodies at their amino groups with retention of antigen-binding activity. , 1987, Journal of immunological methods.

[16]  T. Okano,et al.  Toxicity and antitumor activity against solid tumors of micelle-forming polymeric anticancer drug and its extremely long circulation in blood. , 1991, Cancer research.

[17]  J. Murray,et al.  Lack of comparability between binding of monoclonal antibodies to melanoma cells in vitro and localization in vivo. , 1989, Journal of the National Cancer Institute.

[18]  K. Ulbrich,et al.  Anticancer agents coupled to N-(2-hydroxypropyl)methacrylamide copolymers. 3. Evaluation of adriamycin conjugates against mouse leukaemia L1210 in vivo , 1989 .

[19]  T M Allen,et al.  Large unilamellar liposomes with low uptake into the reticuloendothelial system , 1987, FEBS letters.

[20]  H. Ishitsuka,et al.  Experimental cancer cachexia induced by transplantable colon 26 adenocarcinoma in mice. , 1990, Cancer research.

[21]  K. Isselbacher,et al.  Doxorubicin conjugates of monoclonal antibodies to hepatoma-associated antigens. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[22]  R. Reisfeld,et al.  Doxorubicin conjugated with a monoclonal antibody directed to a human melanoma-associated proteoglycan suppresses the growth of established tumor xenografts in nude mice. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[23]  T. Tsuruo,et al.  4'-O-tetrahydropyranyladriamycin as a potential new antitumor agent. , 1982, Cancer research.

[24]  S. Penco,et al.  Chemical and biological characterization of 4'-iodo-4'-deoxydoxorubicin. , 1987, Cancer research.

[25]  E. Zocchi,et al.  Encapsulation of adriamycin in human erythrocytes. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[26]  R. Paxton,et al.  Effect of specific antibody pretreatment on liver uptake of 111In-labeled anticarcinoembryonic antigen monoclonal antibody in nude mice bearing human colon cancer xenografts. , 1989, Cancer research.

[27]  R K Jain,et al.  Delivery of novel therapeutic agents in tumors: physiological barriers and strategies. , 1990, Journal of the National Cancer Institute.

[28]  A. Rolland,et al.  Enhancement of adriamycin antitumor activity by its binding with an intracellular sustained-release form, polymethacrylate nanospheres, in U-937 cells. , 1988, Cancer research.

[29]  T. Tsuruo,et al.  A fluorine-containing anthracycline (ME2303) as a new antitumor agent against murine and human tumors and their multidrug-resistant sublines. , 1989, Cancer research.

[30]  T. Okano,et al.  Preparation of micelle-forming polymer-drug conjugates. , 1992, Bioconjugate chemistry.

[31]  F. Zunino,et al.  Poly-L-aspartic acid as a carrier for doxorubicin: a comparative in vivo study of free and polymer-bound drug. , 1985, British Journal of Cancer.